📄 Cross-examination of Roger Martz (morning) — Wednesday, July 26, 1995
Address:
C:\DEPT103\CRIMINAL\1995\JUL\26\CROSS-EXAMINATION-OF-ROGER-MAR.DOC
TRIAL
▲ Day 122 of 167

Cross-examination of Roger Martz (morning)

Witness: Roger Martz
Examiner: Marcia Clark
Called by: Defense • Date: Wednesday, July 26, 1995 • Utterances: 364
Marcia Clark cross-examines FBI chemist Roger Martz, methodically establishing the critical distinction between 'detecting' and 'identifying' a chemical compound, then using that distinction to undermine the defense's EDTA-planting theory. Through a series of comparison graphs, Martz confirms that the blood on the sock and rear gate produced signals indistinguishable from unpreserved blood — including his own — and that EDTA was never positively identified in the evidence stains, only that it 'could be present.'
1 MS. CLARK:

Good afternoon, ladies and gentlemen.

THE JURY: Good afternoon.

CROSS-EXAMINATION (RESUMED) BY MS. CLARK

2 MS. CLARK:

All right, sir. Where we left off we were talking about the high pressure liquid chromatography test that you did on the blood samples. Do you recall that?

3 MR. MARTZ:

Yes, I do.

4 MS. CLARK:

I believe you indicated that that particular test, the HPLC, was just a screening test that you would not rely on for any conclusion? Do you recall that testimony?

5 MR. MARTZ:

Yes. That is a screening test and you would not use that for identification.

6 MS. CLARK:

For identification?

7 MR. MARTZ:

That is correct, yes.

8 MS. CLARK:

So there is a difference then between the kind of test that will give you some indication of what might be present versus a test that will give you a definitive answer that something can be identified?

9 MR. MARTZ:

That's correct, yes.

10 MS. CLARK:

You were present during Dr. Rieders' testimony in court the other day, were you not, sir?

11 MR. MARTZ:

Yes, I was.

12 MS. CLARK:

And do you recall, when I began to question him concerning the work he did in the case that we called the Sconce case, People versus Sconce?

13 MR. MARTZ:

Yes.

14 MS. CLARK:

And in that case he was retained to answer the question as to whether or not the victim had been poisoned to death by the use of the oleander plant or died of natural causes. Do you recall that?

15 MR. MARTZ:

Yes, I do.

16 MR. BLASIER:

I'm going to object to this line of questioning without a foundation this agent has personal knowledge of any of this.

17 THE COURT:

Sustained. It is a little premature, but I agree with on you foundational grounds, but it is premature at this point. Proceed.

18 MS. CLARK:

Now, he testified that he used three tests to determine--he used three tests in analyzing the autopsy tissues of the victim; thin layer chromatography, fluorescent spectrometry and radioimmunoassay. Do you recall that?

19 MR. MARTZ:

Yes, I do.

20 MS. CLARK:

And I believe that he testified that those were the best then available methods to test for the presence of oleandrin. Do you recall that testimony, sir?

21 MR. MARTZ:

Yes, I do.

22 MS. CLARK:

Are you familiar with those tests?

23 MR. MARTZ:

Yes, I am.

24 MS. CLARK:

Have you performed them ever?

25 MR. MARTZ:

Yes, I have.

26 MS. CLARK:

Sir, are those tests effective to positively identify a compound?

27 MR. MARTZ:

Well, I will say absolutely yes or no. It would depend on the compound and the circumstances and you would have to review all the data. It is possible that they could under certain circumstances, but it would depend on the specific chemical you are trying to identify.

28 MS. CLARK:

With respect to oleandrin, do you have an opinion as to whether or not those tests would be effective to positively identify that substance?

29 MR. BLASIER:

Objection, no foundation.

30 THE COURT:

Sustained.

31 MS. CLARK:

Have you ever performed any tests to detect the presence of poisons, sir?

32 MR. MARTZ:

Yes, I have.

33 MS. CLARK:

Have you ever performed any tests to detect the presence of poisons such as oleandrin?

34 MR. MARTZ:

Well, every chemical is a little different, but we have identified chemicals that are similar, but not that specific chemical.

35 MS. CLARK:

Are there--are the same tests--for the purpose of identifying a particular poison and of the family similar to that of oleandrin, do you use the same kind of tests for that family of chemicals, poisons such as oleandrin?

36 MR. MARTZ:

Well, at the FBI we primarily rely on mass spectrometry to do our identifications.

37 MS. CLARK:

And in that regard, sir, do you have an opinion as to whether or not the thin layer chromatography radioimmunoassay and fluorescent spectrometry tests are more or less effective than mass spectrometry for the purpose of detection of poisons?

38 MR. BLASIER:

Your Honor, irrelevant unless he is talking about oleander.

39 THE COURT:

Overruled.

40 MR. MARTZ:

They could all be used for determining whether or not it could be present, but for the identification, I would rely on the mass spectrometry to identify that chemical.

41 MS. CLARK:

So for the purpose of identifying poisons, sir, would the tests used by Dr. Rieders be most appropriately characterized as screening tests?

42 MR. BLASIER:

Objection, no foundation.

43 THE COURT:

Sustained. "Poisons" is awfully vague, counsel.

44 MS. CLARK:

For the compound known as oleandrin, sir, do you have any knowledge of the composition of that compound?

45 MR. MARTZ:

I've looked at the chemical and I know--basically I know what it looks like. I couldn't draw the structure or give you the formula for it.

46 MS. CLARK:

If you, sir, were asked--if you were asked in the year 1988 to analyze autopsied tissues to determine whether or not you could identify oleandrin in those tissues, would you have used thin layer chromatography, radioimmunoassay and fluorescent spectrometry?

47 MR. BLASIER:

Objection, calls for speculation.

48 THE COURT:

Overruled.

49 MR. BLASIER:

Irrelevant.

50 THE COURT:

Overruled.

51 MR. MARTZ:

To detect it or identify it?

52 MS. CLARK:

To identify it?

53 MR. MARTZ:

No, I would use mass spectrometry.

54 MS. CLARK:

Because?

55 MR. MARTZ:

It is a definitive test.

56 MS. CLARK:

And the other three that I have outlined are not?

57 MR. MARTZ:

They are not definitive tests in themselves, no.

58 MS. CLARK:

Was mass spectrometry available back in 1988?

59 MR. MARTZ:

Yes, it was.

60 MS. CLARK:

As a matter of fact, as of 1988 did the liquid chromatograph tandem mass spectrometer exist?

61 MR. MARTZ:

Yes, it did.

62 MS. CLARK:

Do you know when it first became available?

63 MR. MARTZ:

Well, there has been many forms of liquid chromatography mass spectrometry in the FBI. We have used various forms since about 1986.

64 MS. CLARK:

1986?

65 MR. MARTZ:

Yes.

66 MS. CLARK:

Now, you yourself at the FBI use the machine known as the liquid chromatograph tandem mass spectrometer, correct?

67 MR. MARTZ:

That's correct.

68 MS. CLARK:

And if you don't mind, from now on I'm going to say LC/MSMS?

69 MR. MARTZ:

Okay.

70 MS. CLARK:

Was that particular--that particular machine was available as of 1986?

71 MR. MARTZ:

The specific one that I used presently was not, but there were other forms of LC/MSMS available in 1986. The electrospray was not commercially available, the one that I am using in 1986.

72 MS. CLARK:

Nevertheless, there were other forms of the LC/MSMS that were available in 1986, correct?

73 MR. MARTZ:

Yes, there were.

74 MR. BLASIER:

Objection, irrelevant.

75 THE COURT:

Overruled. The answer is already in.

76 MS. CLARK:

Would the LC/MSMS, as it existed in 1986 through `88, have been a more effective piece of equipment to use for the identification of oleandrin?

77 MR. BLASIER:

Objection, irrelevant.

78 THE COURT:

Foundation. Sustained. Before that was in existence then?

79 MS. CLARK:

What form of LC/MSMS was in existence back in 1988?

80 MR. MARTZ:

Were several types. One was a direct liquid injection. They had a moving belt. There were several different types. Probably thermospray was available then. There are many different forms of LC/MS.

81 MS. CLARK:

Are you familiar with the in manner which they are operated and the substances that they can most effectively identify?

82 MR. MARTZ:

Yes, I am.

83 MS. CLARK:

And would the LC/MSMS, the forms that existed then, back in 1988, would one of them or all of them have been a more effective means of identifying oleandrin than the tests used by Dr. Rieders?

84 MR. BLASIER:

Objection. No foundation. He has never tested this.

85 THE COURT:

Overruled.

86 MR. MARTZ:

Yes, the LC/MSMS would be a more effective way to identify oleandrin.

87 THE COURT:

All right. Let's move on.

88 MS. CLARK:

Now, you talked, sir--just now you mentioned something about detection versus identification. Can you please tell us what you mean when you say something is detected?

89 MR. MARTZ:

Well, detecting is--is used in a general term in the laboratory. We have certain tests called spot tests, and for something like cocaine, you would do a spot test and you get a color and you could say cocaine was detected, but what you have to realize is there is many other chemicals that would also give similar results, so even though it was detected with that particular test, it doesn't mean it was identified. In order to identify something, you have to use a positive means of identification and in the FBI laboratory we use mass spectrometry as a positive way to identify something based on a full mass spectrum.

90 MS. CLARK:

So when you detect, that means something could be present?

91 MR. MARTZ:

That's correct.

92 MS. CLARK:

But when you identify, you say it is?

93 MR. MARTZ:

That's correct.

94 MS. CLARK:

I notice that when you were being examined by Mr. Blasier he asked you specifically whether or not on one of the evidence stains there was ions consistent with EDTA. Do you recall that?

95 MR. MARTZ:

Yes, I do.

96 MS. CLARK:

And do you recall answering the question yes?

97 MR. MARTZ:

Yes.

98 MS. CLARK:

Consistent with?

99 MR. MARTZ:

Right, correct.

100 MS. CLARK:

When you say "Consistent with," do you mean that you have identified the compound or do you mean that it has been detected, that is, it could be there but you have not identified it?

101 MR. MARTZ:

When something is consistent with something else, it is not a positive identification. It could be something else. With preliminary tests that you do in the laboratory, there is a lot of chemicals that could be consistent, but in order to identify something, you have to have something unique associated with that chemical before you can positively identify it and that is what a mass spectrum does. Some people will say that a mass spectrum, a full mass spectrum, is a fingerprint of a chemical and that is why we try to do a full mass spectrum, to identify a chemical.

KEY QUOTE
102 MS. CLARK:

Now, in that regard, sir, when you discussed this issue with Mr. Blasier in Washington or over the telephone, did you inform him of the distinction between consistent and identified?

103 MR. MARTZ:

Yes, I did.

104 MS. CLARK:

And in this case, sir, in the evidence stains and in your own blood, I believe you testified earlier could you not find the full daughter, the full daughter spectrum?

105 MR. BLASIER:

Objection, asked and answered.

106 THE COURT:

Overruled.

107 MR. MARTZ:

That's correct.

108 MS. CLARK:

And that was the one you could not find the 132 ion?

109 MR. MARTZ:

The 132, the 160 and the 293 in a certain ratio.

110 THE COURT:

I think we have examined on this yesterday.

111 MS. CLARK:

Just foundational to the graph, your Honor.

112 MS. CLARK:

Now, you indicated you tested your own blood on May 11th?

113 MR. MARTZ:

Correct.

114 MS. CLARK:

And you did so with and without EDTA?

115 MR. MARTZ:

Yes.

116 MS. CLARK:

I would like to show you some graphs, sir. And you generated graphs as a result of those tests?

117 MR. MARTZ:

Yes, I did.

118 MS. CLARK:

And those graphs were made to depict the results that you obtained?

119 MR. MARTZ:

Correct.

120 MS. CLARK:

Your Honor, I have a series of three graphs. May they be marked People's 549--548?

121 THE COURT:

548.

122 THE CLERK:

549.

123 MS. CLARK:

549.

124 (Peo's 549-A b, c for id = graphs)
125 THE COURT:

A, b and c?

126 MS. CLARK:

That is what I--yeah, thank you. 549-A will be the chart entitled "Operator blood, no EDTA added," red top with a start time of ten o'clock and 21 seconds. The second one 549-B, "Operator blood with EDTA." And the third one, "Operator blood, no EDTA added" time start, 10:19:55, that will be 549-C.

127 (Brief pause.)
128 THE COURT:

Proceed.

129 MS. CLARK:

Sir, putting up on the elmo 549-A, first of all. Can you see--we can just show him the top label, Mr. Fairtlough, so you can make sure that is what--

130 MR. MARTZ:

Yes.

131 MS. CLARK:

All right. Pushing it over to the left, if you could see the start time, what does that mean?

132 MR. MARTZ:

That is the time that the analysis began, ten o'clock in the morning.

133 MS. CLARK:

Now, these printouts all reflect a certain time for starting?

134 MR. MARTZ:

That's correct.

135 MS. CLARK:

We talked a little bit about the variation in quantification that will occur as a result of the sensitivity of the column. Do you recall that?

136 MR. MARTZ:

Yes.

137 MS. CLARK:

Is it then important to run all of your samples at the same time?

138 MR. MARTZ:

Yes, it is.

139 MS. CLARK:

And in that way will you get an accurate ratio? In other words, they will all run in the same way so you will see them relate to each other in an appropriate more accurate fashion?

140 MR. MARTZ:

It is best to run the samples very close together in order to get the best quantitation.

141 MS. CLARK:

And the most accurate ratio between them?

142 MR. MARTZ:

That's correct.

143 MS. CLARK:

By "Ratio" I mean relative peaks. In other words, if one is very high and one is very low, if you run them at the same time, would that relative height and depth be accurate?

144 MR. MARTZ:

Well, it depends on your definition of "Accurate." It is not going to be a hundred percent accurate, but the closer you can run your sample together, the better off you are.

145 MS. CLARK:

All right. Now, is this the run that you did on May 11th of 1995 on your own blood that you put into a red-topped tube that did not contain EDTA?

146 MR. MARTZ:

Yes.

147 MS. CLARK:

And can you describe for us what is shown in this graph?

148 MR. MARTZ:

This is the reconstructed ion of 160 which is an ion produced from the 293 parent of EDTA.

149 MS. CLARK:

Now, there is a peak shown there, correct?

150 MR. MARTZ:

Yes, there is.

151 MS. CLARK:

What does that indicate?

152 MR. MARTZ:

It indicates that EDTA could be present.

153 MS. CLARK:

Based on this reading, would you identify EDTA as being present?

154 MR. MARTZ:

No, I would not.

155 MS. CLARK:

Does this bear any similarity, this test run on your own blood, without EDTA, does this bear any similarity to the results obtained when the evidence stains were run?

156 MR. MARTZ:

These are very similar results I got as to the stain from the sock and from the gate.

157 MS. CLARK:

Now, I'm going to show you, sir--I'm going to show you the next one--I'm going to show you 549-C. If you can read that, is that again a test of your own blood with no EDTA added on May 11th?

158 MR. MARTZ:

Yes, it is.

159 MS. CLARK:

Start time of 10:19 and 55 seconds?

160 MR. MARTZ:

That's correct.

161 MS. CLARK:

Now, was this also from a red-capped tube?

162 MR. MARTZ:

This was a repeat of the other injection. I just repeated the same solution.

163 MS. CLARK:

And can you describe for us what the result is as depicted in this photograph?

164 MR. MARTZ:

Again, it is indication that EDTA could be present in my blood.

165 MS. CLARK:

And this is the blood from the tube that does not contain EDTA?

166 MR. MARTZ:

That's correct.

167 MS. CLARK:

From that result would you form the opinion that there was EDTA present?

168 MR. MARTZ:

No, I would not. There is not sufficient data to identify EDTA.

169 MS. CLARK:

And that is because?

170 MR. MARTZ:

Umm, this is just a chromatogram with one daughter ion; it is not a full daughter spectrum.

171 MS. CLARK:

And for the full daughter spectrum, that would be that would allow you to identify EDTA, would you have to see the 132 daughter ion?

172 MR. MARTZ:

That's correct.

173 MS. CLARK:

Now then, did you run your blood with EDTA added?

174 MR. MARTZ:

Yes, I did.

175 MS. CLARK:

Showing you 549-B, sir, is this the graph that depicts the run in which you ran your blood with EDTA added?

176 MR. MARTZ:

Yes, it is.

177 MS. CLARK:

Can you tell us what the result is shown in this graph?

178 MR. MARTZ:

The result--again, there is indications that EDTA could be present in this particular blood sample.

179 MS. CLARK:

Now, does this have a different appearance than--excuse me--than the evidence stains that you had run?

180 MR. MARTZ:

The peak is larger than the evidence stains.

181 MS. CLARK:

I don't see any, although, jagged random peaks around that one larger peak?

182 MR. MARTZ:

Well, the noise kind of gets buried when you have a large signal.

183 MS. CLARK:

So does this graph demonstrate that the blood, your blood when having EDTA added, gives a strong signal?

184 MR. MARTZ:

That's correct.

185 MS. CLARK:

On the 160 daughter ion?

186 MR. MARTZ:

Yes.

187 MS. CLARK:

Then the random peaks that you call noise on the blood sample of your own blood, without EDTA, does that indicate that the signal for the 160 daughter ion was weak?

188 MR. MARTZ:

That's correct.

189 MS. CLARK:

And is that very similar again to the evidence stains?

190 MR. MARTZ:

It is very similar to the evidence stains.

191 MS. CLARK:

Now, on July 22, sir, did you do some further testing?

192 MR. MARTZ:

Yes, I did.

193 MS. CLARK:

And what was that?

194 MR. MARTZ:

I retested my blood the same blood samples, and got similar results on that day.

195 MS. CLARK:

Your Honor, I have here additional graphs with the date July 22, 1995, "RMM blood, no EDTA." I would ask that it be marked People's 550-A.

196 THE COURT:

So marked.

197 (Peo's 550-A for id = graph)
198 MS. CLARK:

Sir, is RMM on this graph you?

199 MR. MARTZ:

Those are my initials, yes.

200 MS. CLARK:

And again, July 22, 1995, "RMM blood with EDTA," 550-B.

201 (Peo's 550-B for id = graph)
202 MS. CLARK:

And showing you 550-A, sir--

203 MR. BLASIER:

May I see it?

204 MS. CLARK:

I'm sorry.

205 (Discussion held off the record between Deputy District Attorney and Defense counsel.)
206 MS. CLARK:

Showing you 550-A, sir.

207 MR. MARTZ:

Yes.

208 MS. CLARK:

Is that the graph that depicts the test you did on your own blood with no EDTA--no EDTA added on July 22, 1995?

209 MR. MARTZ:

Yes, it is.

210 MS. CLARK:

Can you tell us what is shown in this graph.

211 MR. MARTZ:

Again there is indications that EDTA could be present.

212 MS. CLARK:

And again does this graph also bear a resemblance or similarities to the evidence stains?

213 MR. MARTZ:

Yes, it does.

214 MS. CLARK:

And in what respect?

215 MR. MARTZ:

It gives a low signal comparison to the known EDTA blood standards.

216 MS. CLARK:

Compared to the known EDTA?

217 MR. MARTZ:

Yes.

218 MS. CLARK:

And showing you 550-B, is this a test of your blood, sir, with EDTA added?

219 MR. MARTZ:

Yes, it is.

220 MS. CLARK:

And based on the results in this graph, would you identify EDTA as being present?

221 MR. MARTZ:

There is indications that EDTA could be present based on the 160 daughter ion.

222 MS. CLARK:

Now, does this graph again demonstrate the same difference that you saw when you ran the known reference samples that you knew to contain EDTA that were taken from the EDTA tube in this case?

223 MR. MARTZ:

Yes, it is very similar results.

224 MS. CLARK:

In what respect?

225 MR. MARTZ:

It is a very large abundance of the 160 ion.

226 MS. CLARK:

Now, did you also attempt to conduct a test that would tell you whether or not you could find EDTA after a period of time?

227 MR. MARTZ:

Yes, I did.

228 MS. CLARK:

And in that respect what did you do?

229 MR. MARTZ:

Well, I took some old blood samples that we had in the laboratory and analyzed those.

230 MS. CLARK:

And how old were they?

231 MR. MARTZ:

Umm, one of them I believe was from 1991 and the other two were from 1993.

232 (Discussion held off the record between Deputy District Attorney and Defense counsel.)
233 MS. CLARK:

Two more charts, your Honor. Entitled July 22, 1995, "EDTA blood from 1993," People's 5--

234 THE COURT:

551.

235 MS. CLARK:

Thank you. 551-A.

236 THE COURT:

Fine. A and B.

237 MS. CLARK:

And the second one, B.

238 (Peo's 551-A & b for id = charts)
239 THE COURT:

Proceed.

240 MS. CLARK:

Showing you People's 551-A, is this the photograph that depicts your testing of a stain from 1993 that was known to contain EDTA?

241 MR. MARTZ:

Yes, it is.

242 MS. CLARK:

And what do you see on this graph, sir?

243 MR. MARTZ:

Again there is a very large abundance of the 160 ion.

244 MS. CLARK:

And did that look--did that bear any similarity to the known reference sample stains that you created in this case taken from the vial of the Defendant and Nicole Brown?

245 MR. MARTZ:

Very similar results, yes.

246 MS. CLARK:

In that--

247 MR. MARTZ:

A very large abundance of the 160 ion.

248 MS. CLARK:

And 551-B, is this--does this graph depict the other tests that you ran on 1993 blood known to contain EDTA?

249 MR. MARTZ:

Yes.

250 MS. CLARK:

Now, based on these--this finding, the blood from 1993 that was known to contain EDTA, did you form some opinion about how stable the compound is or how long it will last?

251 MR. MARTZ:

This pretty much beared out what I suspected, that EDTA is a very stable chemical and I didn't see any degradation of the EDTA over the two-year time period.

252 MS. CLARK:

Now, as a general proposition, sir, are the chemicals found in blood more stable when blood is dried or when it is wet?

253 MR. MARTZ:

Umm, most chemicals are much more table when they are dry than when they are wet.

254 MS. CLARK:

So for example, if you have blood that is deposited on a rear gate, that dries quickly on that rear gate, would the chemical in that blood be more stable and more easily detected after a period of time than if they--the blood was in a wet pool of blood?

255 MR. BLASIER:

Objection, no foundation.

256 THE COURT:

Sustained.

257 MS. CLARK:

Sir, are you familiar with the properties of chemicals found in blood and how they degrade?

258 MR. MARTZ:

Yes, I am.

259 MS. CLARK:

And are you familiar with the conditions that will cause the chemical properties of blood to degrade or be preserved?

260 MR. MARTZ:

Yes, I am.

261 MS. CLARK:

And is that part of your job, sir?

262 MR. MARTZ:

Yes.

263 MS. CLARK:

And part of your training?

264 MR. MARTZ:

Yes, it is.

265 MS. CLARK:

And in your experience and your opinion as an expert in this field, sir, will the chemical properties of blood be better preserved if the bloodstain is dried than if it is in a wet pool?

266 MR. MARTZ:

Most of the chemicals that I deal with, they are much more stable dry than they are in a wet condition.

267 MR. BLASIER:

Objection, move to strike, nonresponsive.

268 THE COURT:

Overruled.

269 MS. CLARK:

And the 1993 samples that you tested, sir, were those wet?

270 MR. MARTZ:

No, they were dry bloodstains.

271 MS. CLARK:

Okay. And were they--what substrate? What were they on?

272 MR. MARTZ:

They were on cotton.

273 MS. CLARK:

I have a graph, your Honor, entitled "EDTA analysis July 22, 1995," People's 552.

274 THE COURT:

552.

275 (Peo's 552 for id = graph)
276 MS. CLARK:

Showing you People's 552, sir, can you tell us what you have depicted in this photograph, in this chart?

277 MR. MARTZ:

Those were the blood samples, some of the ones that I ran on the 22nd.

278 MS. CLARK:

Now, it shows on this chart you ran a blank?

279 MR. MARTZ:

That's correct.

280 MS. CLARK:

And what does that mean?

281 MR. MARTZ:

Generally between runs you will run a blank, just a solvent to show that there is no carry-over.

282 MS. CLARK:

And in this case does this graph depict that the blank was flat, no EDTA?

283 MR. MARTZ:

That's correct.

284 MS. CLARK:

And then you have a 50 parts per millimeter--I'm sorry, per million?

285 MR. MARTZ:

That's correct, yes.

286 MS. CLARK:

And that--what was the purpose of running that?

287 MR. MARTZ:

Just to show that the instrument was working.

288 MS. CLARK:

That it did detect a known standard of 50 parts per million?

289 MR. MARTZ:

Not necessarily 50 parts per million; to show that it will detect EDTA in that it is fairly sensitive.

290 MS. CLARK:

Then you have the 1993 1 and 1993 2. What do those show?

291 MR. MARTZ:

Those were the two bloodstains that were preserved in the FBI laboratory since 1993. They were extracted, they were known EDTA blood standards and they showed very high levels of EDTA.

292 MS. CLARK:

Okay. Now, you have come to the section that says "RMM, no," and what does that stand for?

293 MR. MARTZ:

That depicts my blood which is not preserved with EDTA.

294 MS. CLARK:

Now, is there some reading indicated on this that it is a little bit higher than the blank?

295 MR. MARTZ:

Yes, there was some reading and that was shown on the chromatograms we had seen earlier.

296 MS. CLARK:

And was that where you said you ran it for the daughter 160?

297 MR. MARTZ:

That's correct.

298 MS. CLARK:

Thank you, Mr. Fairtlough.

299 MS. CLARK:

Could you show us now then the blank and then the last column showing your blood--thank you--showing your blood with EDTA added?

300 MR. MARTZ:

That's correct.

301 MS. CLARK:

Okay. On this graph, sir, on this chart, can you tell us whether the results shown for your blood where it says "RMM, no," where you have not added EDTA and "RMM, yes," where you have added EDTA to your blood, bears any relationship or similarity to the comparison of the blood taken from the reference files of the Defendant and Nicole Brown and the evidence stains in this case from the gate and the sock?

302 MR. MARTZ:

Yes. There was a very clear comparison. My blood that was preserved and Mr. Simpson and Mrs. Simpson's bloods that were preserved all contained a large amount of EDTA and my blood that was not preserved and the stain from the gate and the sock all showed indications of the 160 ion, but in none of those cases was I able to identify EDTA.

303 MS. CLARK:

Because of the lack of the full daughter spectrum?

304 MR. MARTZ:

That's correct.

305 MS. CLARK:

Now, sir, in your job, is it unusual for you to discover new compounds, new chemicals?

306 MR. BLASIER:

Objection, asked and answered.

307 THE COURT:

Overruled.

308 MR. MARTZ:

I would say different, not necessarily new. They are chemicals that have existed and it is the first time that we identified them.

309 MS. CLARK:

Okay. Now, does that--does the fact that you identify--would you say it is a routine thing to identify chemicals that you have not previously identified?

310 MR. MARTZ:

That's correct.

311 MS. CLARK:

In that light, sir, in light of the fact that you routinely do identify new chemicals not previously identified, does that highlight the importance of refraining from identifying a compound until you see all of the characteristics that must be present, such as in this case the full daughter spectrum of 160 and 132 before you are ready to identify it as EDTA?

312 MR. MARTZ:

Yeah, it is very, very important. You don't want to jump to any conclusions because there are a lot of chemicals in the world. There are at least eleven million that are known and I'm sure there is more and a lot of those have similar properties, and you must be very, very careful before you positively identify one of those chemicals.

313 MS. CLARK:

In doing so, in settling for two out of the three factors in this case, if you settle for the parent 239 and the daughter 160 without looking for the other daughter of 132, identifying EDTA when you see only two out of the three could cause a mistake to be made?

314 MR. MARTZ:

In my opinion that could cause a mistake, yes.

KEY QUOTE
315 MS. CLARK:

Now, sir, when you were asked the question by us as to whether or not--when you were asked by the District Attorney's office to look at the bloodstains in this case to determine whether or not EDTA was present, did anyone from our office tell you what test to conduct?

316 MR. MARTZ:

No, they did not.

317 MS. CLARK:

Did you ever ask our permission before conducting any particular test?

318 MR. MARTZ:

I think I had called rock up when I did the second test to make sure that I could use more sample, but that was the only time. When I initially conducted the tests I didn't ask permission from anybody, no.

319 MS. CLARK:

The reason that you contacted Mr. Harmon was to find out if could you get more of the sample so you could run more tests?

320 MR. MARTZ:

That's correct.

321 MS. CLARK:

You were not asking his permission as a scientist to allow you to perform tests that you felt were scientific?

322 MR. MARTZ:

No, I was not.

323 MS. CLARK:

If in your judgment, sir, there were tests that you felt were appropriate to be conducted, were scientifically appropriate to be conducted, would you await our permission before conducting that test?

324 MR. MARTZ:

No, I would not.

325 MS. CLARK:

If we asked you not to perform a test that you felt was scientifically proper and correct to do, would you accept that and not do it at our say so?

326 MR. MARTZ:

Well, I mean generally I never really talk to the Prosecutors; I just do the case. I work the case and give then the answer is the way that I routinely do analysis.

327 MS. CLARK:

And that is what you did in this case, sir?

328 MR. MARTZ:

Yes, it is.

329 MS. CLARK:

When you attempted to answer the question as to whether or not EDTA from a preserved tube was present in the evidence stains from the gate and the sock, did you then conduct all of the tests that you in your judgment thought were scientifically appropriate to conduct?

330 MR. MARTZ:

Yes, I did.

331 MS. CLARK:

And what answer did you obtain?

332 MR. MARTZ:

I was able to determine that the bloodstains on the sock and the gate did not come from preserved blood.

KEY QUOTE
333 MS. CLARK:

Thank you, sir.

334 THE COURT:

Mr. Blasier.

335 MR. BLASIER:

Thank you, your Honor.

336 MS. CLARK:

I'm sorry, may I mark the charts, your Honor?

337 THE COURT:

Yes.

338 (Discussion held off the record between the Deputy District Attorneys.)
339 THE COURT:

Mr. Blasier.

340 MR. BLASIER:

Thank you, your Honor.

341 MS. CLARK:

Excuse me, your Honor, I hadn't completed--if I may.

342 (Discussion held off the record between the Deputy District Attorneys.)
343 THE COURT:

Which charts do you need to mark?

344 MS. CLARK:

These were from yesterday, your Honor. I would like to--

345 THE COURT:

All right. Proceed.

346 MR. BLASIER:

Thank you, your Honor.

347 THE COURT:

I'm sorry, I was directing my comments to Miss Clark.

348 MR. BLASIER:

I'm sorry.

349 (Brief pause.)
350 MS. CLARK:

Okay. The charts that reflect the graphs that reflect the runs for the evidence stains for the full daughter spectrum, 543-E, which is a combination of 543 a and C.

351 THE COURT:

All right.

352 (Peo's 543-E for id = chart)
353 MS. CLARK:

543-F is the combination of the charts 543-D and B.

354 (Peo's 543-F for id = chart)
355 MS. CLARK:

544-E is a combination of the charts 544-A and B.

356 (Peo's 544-E for id = chart)
357 MS. CLARK:

And 544-F is a combination of the charts 544-C and D.

358 THE COURT:

Fine. Thank you.

359 (Peo's 544-F for id = chart)
360 MS. CLARK:

May I conclude with one last question, your Honor?

361 THE COURT:

Proceed.

362 (Discussion held off the record between the Deputy District Attorneys.)
363 MS. CLARK:

Never mind, your Honor. I'm sure it will become germane again. I will conclude with this. Thank you.

364 THE COURT:

Mr. Blasier.

Temperature

tense

Key Quotes (5)

Roger Martz
I was able to determine that the bloodstains on the sock and the gate did not come from preserved blood.
Clark's closing punch: the FBI's own chemist, called by neither side as a champion, delivers the prosecution's core rebuttal to the planting theory in a single sentence.
Roger Martz
When something is consistent with something else, it is not a positive identification. It could be something else.
Directly neutralizes Blasier's earlier cross, where Martz had said ions 'consistent with EDTA' were found — Clark gets Martz to clarify that 'consistent with' is not identification.
Roger Martz
In my opinion that could cause a mistake, yes.
Martz agrees that finding only two of three required spectral markers and calling it EDTA — as Rieders effectively did — is an error-prone approach.
Roger Martz
You don't want to jump to any conclusions because there are a lot of chemicals in the world. There are at least eleven million that are known and I'm sure there is more and a lot of those have similar properties.
Frames the defense's expert Rieders as having done exactly what a careful scientist should not do.
Roger Martz
My blood that was preserved and Mr. Simpson and Mrs. Simpson's bloods that were preserved all contained a large amount of EDTA and my blood that was not preserved and the stain from the gate and the sock all showed indications of the 160 ion, but in none of those cases was I able to identify EDTA.
The evidentiary core of the cross: evidence stains cluster with unpreserved blood, not with EDTA-preserved reference samples.

Evidence (6)

People's 549-A, B, C
Graphs of Martz's own blood tested with and without EDTA on May 11, 1995
introduced and discussed to establish baseline comparison
People's 550-A, B
Graphs of Martz's own blood tested with and without EDTA on July 22, 1995
introduced and discussed to confirm May results
People's 551-A, B
Graphs of FBI lab blood samples from 1993 known to contain EDTA
introduced to show EDTA stability over time and strong signal in known samples
People's 552
Summary chart of July 22 EDTA analysis comparing blank, known standards, 1993 stains, and Martz's blood with/without EDTA
introduced and discussed as visual summary of all comparisons
People's 543-E, 543-F, 544-E, 544-F
Combined charts depicting full daughter spectrum runs for the evidence stains (sock and gate)
formally marked at close of examination; referenced as basis for inability to identify EDTA
Informal
Blood reference samples from OJ Simpson and Nicole Brown's EDTA-preserved collection tubes
discussed as known EDTA-positive comparators showing large 160 ion abundance

Notable Exchanges (3)

Marcia ClarkRoger Martz
Clark walks Martz through the detect/identify distinction, then circles back to show that Blasier's 'consistent with EDTA' framing during direct was, by Martz's own definition, not an identification — effectively re-characterizing the defense's headline finding as a non-finding.
strategic
Marcia ClarkRoger Martz
Clark uses the Sconce case to imply Dr. Rieders used inferior screening tests (TLC, fluorescent spectrometry, radioimmunoassay) when more definitive mass spectrometry was available, establishing that Rieders' methodology was deficient even by 1988 standards.
methodical impeachment by proxy
Marcia ClarkRoger Martz
Clark has Martz confirm that his independence from prosecutorial direction was complete — he chose his own tests and would not have stopped a test at the DA's request — preempting any defense narrative of prosecution-controlled results.
revealing

Credibility Attacks (2)

⚔ Fredric Rieders
methodology attack via prior case (Sconce) and expert comparison
Clark establishes through Martz that the three tests Rieders used to identify oleandrin in Sconce — and by analogy, EDTA here — are screening tests, not definitive identification tests, and that the superior LC/MSMS technology was available as early as 1986. She implies Rieders used an inferior toolkit and drew conclusions he was not entitled to draw.
⚔ Roger Martz (defensive rehabilitation)
preemptive rebuttal of bias/control narrative
Clark elicits that Martz conducted his tests entirely on his own scientific judgment, did not ask the prosecution's permission, and would not have deferred to the DA's office if they had objected — insulating his conclusions from the defense's implied narrative that the prosecution shaped the results.

Objections

13 objections (4 sustained, 9 overruled)
Proceeding 7039 • 364 utterances • Defense witness
Criminal Trial
Department 103
⚖️ Start
📂 JUL 26, 1995 📄 Cross-examination of Roger Mar
JUL 26, 1995 KRT DvH TD